Code intelligence

FDA-NDA016673 reimbursement alerts

Policy changes, MAC LCD updates, and CMS guidance referencing code FDA-NDA016673.

Critical code risk

Signal breakdown

1 shown · 1 total in platform

Risk: Critical

Critical

100%

High

Routine

Low

New this month

alerts added in last 30 days

Effective soon

—

no upcoming deadlines

FDA Approval: DEXTROSE (DEXTROSE MONOHYDRATE) — Type 5 - New Formulation or New Manufacturer

Policy FDA-NDA016673 · Multi-specialty

Critical

The recent approval of Dextrose (Dextrose Monohydrate) as an injectable drug indicates it will be billed under Medicare Part B, likely with an assigned J-code. The billing teams should monitor for the

View alert